Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ADXN with free AI briefings, catalyst countdowns, and dilution alerts.

ADXN · Addex Therapeutics Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$767,328 Cash on Hand
3.9mo Cash Runway
Follow ADXN by email Get an email when ADXN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ADXN, unsubscribe in one click. Privacy

📣 What ADXN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dipraglurant Parkinson Disease Phase 2/3 · NCT05116813 Terminated
ADX10059 Gastroesophageal Reflux Phase 2 · NCT00810485 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ADXN holds $767,328 in cash and short-term investments and burns about $596,668/quarter from operations, an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 87 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADXN files for a raise →

👥 Who Owns ADXN

Insiders 15.1% Institutions (2 holders) 0.1% Public and other holders 84.8%
HolderTypeShares% of sharesAs of
Timothy Mark Dyer
CHIEF EXECUTIVE OFFICER, Director · +25.60M options
Insider 16,848,979 11.40% 2026-09-02
Vincent Michael Lawton
Director · +2.89M options
Insider 2,507,987 1.70% 2026-09-02
Raymond George Hill
Director · +1.87M options
Insider 1,365,532 0.92% 2026-09-02
Roger Mills
CHIEF MEDICAL OFFICER, Director · +1.04M options
Insider 785,976 0.53% 2026-09-02
Mikhail Kalinichev
HEAD OF TRANSLATIONAL SCIENCE · +200,000 options
Insider 306,765 0.21% 2026-09-02
Jason Raleigh Nunn
Director · +1.04M options
Insider 219,561 0.15% 2026-09-02
Isaac Manke
Director · +1.04M options
Insider 219,561 0.15% 2026-09-02

Share count 147,831,814 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ADXN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADXN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.